A detailed history of Algert Global LLC transactions in Revolution Medicines, Inc. stock. As of the latest transaction made, Algert Global LLC holds 40,048 shares of RVMD stock, worth $1.73 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
40,048
Previous 40,048 -0.0%
Holding current value
$1.73 Million
Previous $1.55 Million 16.86%
% of portfolio
0.05%
Previous 0.05%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$30.14 - $40.68 $1.01 Million - $1.37 Million
33,588 Added 519.94%
40,048 $1.55 Million
Q1 2024

May 14, 2024

SELL
$26.56 - $33.55 $375,558 - $474,396
-14,140 Reduced 68.64%
6,460 $208,000
Q4 2023

Feb 14, 2024

BUY
$18.35 - $34.12 $378,010 - $702,872
20,600 New
20,600 $591,000
Q1 2023

May 12, 2023

SELL
$20.76 - $30.09 $1.15 Million - $1.66 Million
-55,163 Reduced 50.24%
54,627 $1.18 Million
Q4 2022

Feb 13, 2023

SELL
$17.68 - $25.53 $323,897 - $467,709
-18,320 Reduced 14.3%
109,790 $2.62 Million
Q3 2022

Nov 15, 2022

BUY
$17.46 - $26.0 $1.83 Million - $2.72 Million
104,730 Added 447.95%
128,110 $2.53 Million
Q2 2022

Aug 15, 2022

BUY
$14.54 - $27.17 $339,945 - $635,234
23,380 New
23,380 $456,000
Q4 2021

Feb 14, 2022

SELL
$24.35 - $33.7 $371,873 - $514,666
-15,272 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$23.95 - $33.41 $109,738 - $153,084
4,582 Added 42.86%
15,272 $420,000
Q2 2021

Aug 13, 2021

SELL
$29.0 - $47.44 $4,640 - $7,590
-160 Reduced 1.47%
10,690 $339,000
Q1 2021

May 14, 2021

BUY
$37.21 - $54.43 $25,079 - $36,685
674 Added 6.62%
10,850 $498,000
Q4 2020

Feb 12, 2021

BUY
$30.19 - $45.49 $307,213 - $462,906
10,176 New
10,176 $403,000

Others Institutions Holding RVMD

About Revolution Medicines, Inc.


  • Ticker RVMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,697,600
  • Market Cap $3.8B
  • Description
  • Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...
More about RVMD
Track This Portfolio

Track Algert Global LLC Portfolio

Follow Algert Global LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.